We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$546M
2
WTW icon
Willis Towers Watson
WTW
+$471M
3
MA icon
Mastercard
MA
+$344M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$240M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$238M

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 35.71%
2 Technology 14.95%
3 Financials 13.65%
4 Communication Services 11.15%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FDMT icon
226
4D Molecular Therapeutics
FDMT
$875M
– –
-100,000
Closed -$4.14M
IVA
227
Inventiva
IVA
$1.11B
– –
-160,000
Closed -$2.32M
MASS icon
228
908 Devices
MASS
$441M
– –
-75,000
Closed -$4.27M
MRVL icon
229
CALL
Marvell Technology
MRVL
$213B
– –
-125,000
Closed -$5.94M
NTLA icon
230
Intellia Therapeutics
NTLA
$1.8B
– –
-225,000
Closed -$12.2M
PACB icon
231
Pacific Biosciences
PACB
$420M
– –
-2,100,000
Closed -$54.5M
PRAX icon
232
Praxis Precision Medicines
PRAX
$10.5B
– –
-16,667
Closed -$13.8M
SPRY icon
233
ARS Pharmaceuticals
SPRY
$547M
– –
-47,620
Closed -$2.21M
STTK icon
234
Shattuck Labs
STTK
$756M
– –
-100,000
Closed -$5.24M
XPO icon
235
XPO
XPO
$23.2B
– –
-318,053
Closed -$13.1M
ALPN
236
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-200,000
Closed -$2.52M
ISEE
237
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-754,740
Closed -$5.21M
HMCOU
238
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
– –
-400,000
Closed -$4.41M
TINV.U
239
DELISTED
Tiga Acquisition Corp. Units, each consisting of one Class A ordinary share and one half of one warrant
TINV.U
– –
-1,080,000
Closed -$11.4M
CAS.U
240
DELISTED
Cascade Acquisition Corp. Units, each consisting of one share of Class A Common Stock and one-half o
CAS.U
– –
-990,000
Closed -$10.3M
ACIA
241
DELISTED
Acacia Communications Inc
ACIA
– –
-100,000
Closed -$7.3M
TIF
242
DELISTED
Tiffany & Co.
TIF
– –
-2,287,000
Closed -$301M
BMY.RT
243
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-21,400,000
Closed -$14.8M
6 7 8 9
10

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2021 Portfolio in Review

As of Q1 2021, Thomas Steyer held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Thomas Steyer's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Thomas Steyer added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Thomas Steyer's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Thomas Steyer fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Thomas Steyer's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Thomas Steyer opened 120 new positions and closed 20 in Q1 2021.
  • Thomas Steyer's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.